Skip to main content

Table 1 Clinical and pathological characteristics of breast cancer patients

From: Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients

Patient Menopause status Histologic type Histological grading B classification MIB-1 [%] Receptor status Molecular subtype
ER PR HER2/neu
1 Post IDC G2 B5b 10 +++ ++ Luminal A
2 Post IDC G2 B5b 10 +++ ++ Luminal A
3 Peri IDC G3 B5b 30 +++ Luminal A
4 Pre IDC G2 B5b 40 +++ ++ +++ Luminal B
5 Post IDC G2 B5b 60 +++ ++ Luminal A
6 Pre IDC G3 B5b 50 +++ +++ +++ Luminal B
7 Post IDC G3 B5b 20 pos. pos. Luminal A
8 Post IDC G2 B5b 20 +++ +++ Luminal A
9 Post IDC G3 B5 30 ++ +++ Luminal A
10 Post IDC G3 B5b 20 +++ +++ + Luminal B
11 Post IDC G1 B5c 20 +++ +++ + Luminal B
12 Post IDC G3 B5b 70 Triple negative
13 Pre ILC n.s. B5b 50 +++ ++ Luminal A
14 Pre IDC G3 B5b 80 ++ Luminal A
15 Post IDC G3 B5b 40 +++ ++ Luminal A
16 Post ILC G2 B5b 30 +++ +++ Luminal A
17 Pre Mucinous G2 B5b 50 +++ ++ +++ Luminal B
18 Post IDC G3 B5b 50 +++ HER2/neu
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, MIB-1 mindbomb E3 ubiquitin protein ligase 1 (proliferative activity), ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2, n.s. not specified, + weakly positive, ++ moderately positive, +++ strongly positive, − negative